Takeda Pharmaceutical (TSE:4502) Could Be 13% Undervalued After Fresh Psoriasis Trial Data
Takeda Pharmaceutical (TSE:4502) just put fresh late stage psoriasis data in front of investors, with its oral TYK2 inhibitor zasocitinib showing statistically superior skin clearance versus deucravacitinib in three Phase 3 LATITUDE trials.
Despite the zasocitinib update and a busy September that included fresh oncology data announcements and a senior public affairs appointment in Spain, Takeda Pharmaceutical’s share price has eased over the past week and month. However, the 90 day share price return of 6.6% and year to date share price gain of 16.2% sit alongside a 1 year total shareholder return of 37.6% and 5 year total shareholder return of 119.8%, indicating momentum that has been building over a longer stretch rather than fading.
Scan how Takeda Pharmaceutical’s momentum compares with other healthcare players by checking out a curated set of 10 healthcare AI stocks aligned with similar treatment and technology themes.
Takeda Pharmaceutical shares have cooled after a strong run, even as zasocitinib headlines keep coming. Is it more reasonable to lean into the current reset, or to wait for a lower entry point before a potential next move?
Most Popular Narrative: 13% Undervalued
On the most followed view, Takeda Pharmaceutical’s fair value sits at ¥6,603 per share, which compares to the latest close of ¥5,712 and frames the recent pullback as a move that still leaves a valuation gap on the table.
The anticipated moderation and eventual stabilization of VYVANSE generic erosion after FY2025 will remove a major headwind for revenues, allowing Takeda's core growth and launch products to drive top-line and earnings recovery going forward.
Rapid progress and positive late-stage data from Takeda's innovative pipeline, especially in high-need therapeutic areas like rare diseases (orexin agonists for narcolepsy, rusfertide for polycythemia vera), set the stage for multiple high-value product launches, which can catalyze multi-year revenue and margin expansion.
See why 17 investors see Takeda Pharmaceutical as 13% undervalued.
Result: Fair Value of ¥6,603 (UNDERVALUED)
Still, the narrative can unravel if generic and biosimilar pressure on key therapies bites harder than expected or if late stage trials for Takeda Pharmaceutical underperform.
Find out about the key risks to this Takeda Pharmaceutical narrative.
Next Steps
Mixed feelings about Takeda Pharmaceutical after this run of news and the ongoing valuation debate are perfectly reasonable. Take a moment to weigh both sides for yourself, then pressure test your view against the 2 key rewards and 2 important warning signs.
Looking for more Takeda Pharmaceutical sized ideas?
Do not stop with Takeda Pharmaceutical. Broaden your watchlist with fresh angles now, or you risk missing opportunities that better match your risk and return preferences.
- Target potential mispricing by scanning a focused set of companies that screen as attractively valued on quality and fundamentals via the 17 high quality undervalued stocks.
- Lock in income potential by reviewing a curated pool of high yield payers that pair strong distributions with balance sheet support through the 20 dividend fortresses.
- Guard against downside shocks by filtering for businesses that pass strict financial health checks using the list of solid balance sheet and fundamentals (23 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com